The American Joint Committee on Cancer (AJCC) eighth edition staging manual introduced a new prognostic stage for breast cancer incorporating biologic factors in addition to traditional anatomic factors.
T he goals of cancer staging are to determine the extent of disease, help implement a treatment plan, and inform prognosis. Historically, the American Joint Committee on Cancer (AJCC) staging system for breast cancer has assigned stage based on tumor size (T), the presence of lymph node involvement (N), and the presence or absence of distant metastasis (M). The T, N, and M categories are determined, and this corresponds with a specific disease stage.
A significant limitation of the breast cancer TNM staging system is that it does not account for biologic factors known to have predictive and prognostic value, including tumor grade, estrogen receptor (ER) and progesterone receptor (PR) status, and HER2 status. Treatment recommendations and the subsequent response to therapy are dictated by these factors. [1] [2] [3] [4] Therefore, patient prognosis varies within each TNM stage based on biologic features. Recognizing this, the expert panel that recently revised the AJCC staging system incorporated a prognostic stage to take into account biologic factors.
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The prognostic stage was developed using data from 238 265 patients identified in the National Cancer Database treated between 2010 and 2011 in whom complete data were available, including the AJCC TNM stage, tumor grade, and ER, PR, and HER2 status. Prognostic subgroups based on TNM stage, tumor grade, and ER, PR, and HER2 status were determined, and survival calculations were performed. These analyses confirmed that prognosis varied within TNM stage groupings based on tumor biology, leading to the identification of 170 prognostic groups that were assigned to stages 0 to IV. 5, 6 The present study was undertaken to validate this new AJCC prognostic staging system in patients identified in a single-institution cohort (The University of Texas MD Anderson Cancer Center [hereafter MD Anderson] ) and the large population-based California Cancer Registry (CCR) and to compare the relative value of the prognostic stage over the anatomic stage alone. Patients receiving neoadjuvant systemic therapy, those with inflammatory or rare breast cancers, and those with unknown clinicopathologic factors were excluded.
Methods
Patients with invasive breast cancer who underwent surgery as the initial intervention at MD Anderson from 2007 to 2013 were identified from a database maintained prospectively in the Department of Breast Surgical Oncology. The database does not include patients initially seen with stage IV disease. Clinicopathologic data were recorded, including pathologic T and N categories, tumor grade, and ER, PR, and HER2 status. Disease-specific survival (DSS) was calculated from the date of diagnosis to the date of death or last contact. Vital status data were complete through December 31, 2016, in the MD Anderson cohort and through December 31, 2014, in the CCR cohort. Any patient alive at those dates was censored at this time. Patients who died from a cause other than breast cancer were censored onthedateofdeath.
Disease-specific survival according to anatomic and prognostic stages was compared in each cohort. The log-rank test was used to compare differences between groups. The Harrell concordance index (C index) 9 was calculated for the models using the "survival" package in the R Project for Statistical Computing (The R Foundation). 10 The C index measures the proportion of pairs for which the predicted and observed outcomes are concordant and can be interpreted as a measure of the model's predictive performance. A higher C index indicates a better predictive performance. The Akaike information criterion (AIC) 11 was used to compare model fits. A lower AIC indicates a better model. Significance between the C index of the anatomic and prognostic staging models was determined using the "compareC" package in R. After excluding patients in whom a prognostic stage could not be determined, 2876 patients from the MD Anderson cohort and 50 982 patients from the CCR cohort were used in survival analyses. Differences between the total patient cohort and those used for survival analyses only are listed in eTable 4 in the Supplement. The median follow-up was 5 years for the MD Anderson cohort and 7 years for the CCR cohort. Five-year DSS rates for both cohorts by anatomic and prognostic stages are summarized in Table 1 and the Figure. In the MD Anderson cohort, the C index for the prognostic stage was 0.8357, and the AIC was 816.8. For the anatomic stage, the C index was 0.737, and the AIC was 1039.8. The higher C index (P < .001) and the lower AIC of the prognostic stage reflect a more accurate model predictive of DSS than the anatomic stage. In the CCR cohort, the C index for the prognostic stage was 0.8426, and the AIC was 80 661.68. For the anatomic stage, the C index was 0.8097, and the AIC was 81 577.89. The higher C index (P < .001) and the lower AIC again indicate a more accurate model.
The larger population-based CCR cohort was then used to look more closely at the discrimination between stages. Anatomic and prognostic staging of IIB and IIIA patients and IIIB and IIIC patients was examined. The χ 2 statistic, which measures distance between stages, was 4.1302 (P = .04) for anatomic stage IIB to IIIA vs 23.1143 (P < .001) for prognostic stage IIB to IIIA. Comparing stage IIIB with IIIC, the χ 2 statistic was 2.7869 (P = .10) for the anatomic stage vs 135.3551 (P < .001) for the prognostic stage. The larger χ 2 statistic seen among prognostic stages represents a larger and statistically significant difference. Next, a multivariable Cox proportional hazards regression model of survival by stage was performed using stage IA as the reference category for all calculations. The hazard ratios for anatomic and prognostic stages are summarized in Table 2 and the eFigure in the Supplement. 
Discussion
It is accepted that biologic factors, including tumor grade and ER, PR, and HER2 status, as well as genomic assays, are critical for patients with breast cancer because they enable selection of appropriate therapy, thereby influencing outcome. The expert panel convened to revise the AJCC staging system, which included 2 of us (G.N.H. and E.A.M.), believed that these factors are as important as the anatomic extent of disease in predicting survival. 13 Therefore, the panel thought that it was critical to include biologic factors in the eighth edition staging system for the system to maintain relevance in clinical practice. The panel was challenged by the lack of available level 1 evidence to support the influence of biologic factors on prognosis. To address this, an analysis of the available National Cancer Database data was undertaken to identify prognostic stage groups incorporating T, N, and M categories and tumor grade, as well as ER, PR, and HER2 status. This analysis, which at the time of this writing has not been published, led to the development of a prognostic stage in addition to an anatomic stage in the eighth edition of the AJCC staging manual. 5, 6 It is important to note that the prognostic stage was determined using a cohort of patients treated for their breast cancer based on the anatomic extent and biology of their disease and would not be applicable to patients not receiving therapy. Before publication of the AJCC eighth edition staging manual, this prognostic stage had not been validated in additional cohorts. In the present study, we have confirmed that the prognostic stage provides more accurate prognostic information than the anatomic stage in both a single-institution cohort and a large population database. 
Research Original Investigation Validation Study of the AJCC Eighth Edition Prognostic Stage in Breast Cancer
The prognostic stage is consistent with previous work demonstrating the significance of biologic factors in prognosis for patients with breast cancer. In an initial study 14 of 3728 patients treated with surgery as the initial intervention at MD Anderson between 1997 and 2006, a staging system was proposed incorporating tumor grade and ER status along with the pathologic stage that better stratified patients with respect to DSS than the pathologic stage alone. A limitation of that analysis was that it predated the routine use of trastuzumab in patients with HER2-positive tumors. To address this, the work was recently updated, and a Bioscore was proposed, which assigns points based on the AJCC TNM pathologic stage, tumor grade, ER status, and HER2 status. 15 The Bioscore was validated in a cohort of almost 68 000 patients identified in the CCR, suggesting broad applicability. In addition, data available from MD Anderson and the CCR have been used to investigate the risk score, another staging model. 16, 17 The risk score was designed to be a simple system whereby the AJCC anatomic stage was complemented by a risk score determined by assigning points based on tumor grade and ER and HER2 status. A point is assigned for each of the following 3 characteristics: grade 3, ER negative, or HER2 negative. The risk score can range from 0 to 4, thereby allowing for significant separation within each anatomic stage category into 4 risk groups determined by biologic factors. Using the risk score, it was shown that within an anatomic stage category the best outcomes were seen among patients with ER-positive breast cancer, and the worst outcomes were seen among patients with triple-negative disease. Similarly, using the AJCC eighth edition prognostic stage, patients with triple-negative disease, regardless of grade, and patients with grade 3 tumors that do not express either ER or HER2 have decreased survival comparable to that of patients one stage higher by seventh edition criteria.
5
One notable observation in the present study is the percentage of patients in whom a prognostic stage could not be assigned. Prognostic stages could not be assigned due to the presence of micrometastases (pN1mi) in the lymph nodes of patients with tumors larger than 2 cm or due to uncategorized combinations of T and N categories with tumor grade and HR and HER2 status. With respect to the issue of pN1mi disease in patients with tumors larger than 2 cm, this is a limitation of the AJCC anatomic stage that is unchanged between the seventh and eighth editions. The designation of micrometastases (>0.2 to 2.0 mm) in lymph nodes was incorporated into the AJCC staging system with the sixth edition to address the issue of increased detection of small-volume metastases with enhanced pathologic evaluation of sentinel nodes. Initially, T1n1miM0 disease was classified as stage IIA, the same as T1N1M0 disease. Recognizing that the presence of micrometastases may not have the same influence on prognosis as macrometastases, the seventh edition categorized T1N1miM0 disease as stage IB. The utility of the stage IB designation has previously been questioned. 18 To our knowledge, no data have been published looking specifically at the prognostic significance of pN1mi disease in patients with T2 and T3 tumors. Ongoing work by our group is investigating this. With respect to uncategorized combinations of T and N categories with biologic variables, this occurred most often in patients with anatomic stage IIB (T3N0 or T2N1) disease. The issue of uncategorized combinations of T and N categories with tumor grade and HR and HER2 status has been communicated to the AJCC, and we anticipate a forthcoming revision (written communication, Stephen Edge, MD, August 31, 2017). Another consideration that could influence integration of the prognostic stage, which includes 170 prognostic groups, into clinical practice is the complexity. It is unlikely that clinical decisions regarding treatment recommendations will be made based on the prognostic stage because they are routinely guided by the tumor size, nodal status, receptor status, and the results of genomic profiling. Therefore, the prognostic stage is less likely to be used to facilitate communication between health care professionals and is more likely to be used in counseling patients regarding prognosis if they receive the recommended treatment plan. There may also be a role for incorporating the prognostic stage into clinical trial design to more accurately categorize patients with respect to risk.
Limitations
One limitation of the present study is that we do not have complete data regarding administration of trastuzumab in HER2-positive patients. In the MD Anderson cohort, 233 of 306 (76.1%) HER2-positive patients received trastuzumab, including 68.8% of patients with stage I disease, 81.1% of patients with stage II disease, and 97.2% of patients with stage III disease. Data regarding trastuzumab administration are not available for the CCR cohort because the registry does not capture specific agents administered; until 2013, trastuzumab use was coded as chemotherapy. Another limitation of the present study is that we did not have Oncotype DX data available. The eighth edition prognostic stage assigns any patient with T1-T2N0, ER-positive, HER2-negative breast cancer with an Oncotype DX breast recurrence score of 10 or less a stage of IA. This is based on data from the Trial Assigning Individualized Options for Treatment (TAILORx), 19 which was conducted to refine the clinical utility of the Oncotype DX breast recurrence score. In that trial, 1626 patients identified as being at low risk based on having an Oncotype DX breast recurrence score of 10 or less received adjuvant endocrine therapy without chemotherapy. At 5 years, they had exceptional survival outcomes, including an invasive disease-free survival rate of of using this assay in prognostication. At the time the AJCC eighth edition staging manual went to press, these data from the TAILORx were the only level 1 data available evaluating multigene assays. Since that time, data from the Microarray in Node-Negative Disease and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy (MINDACT) trial 22 have shown that women with low genomic risk as determined using the MammaPrint (Agendia) 70-gene breast cancer recurrence assay who, despite having high clinical risk, did not receive adjuvant chemotherapy had high 5-year survival rates comparable to those of patients who received chemotherapy. These data are consistent with the AJCC eighth edition prognostic stage, which downgraded tumors with low genomic risk to stage I, and it is anticipated that these data will be incorporated into future editions. 13 It is possible that data from ongoing trials evaluating the role of genomic assays in node-positive patients will define a role for inclusion of these assays in the staging of patients with node-positive breast cancer. Given data from the TAILORx 19 and the MINDACT trial, 22 it would further improve the stratification between the anatomic and prognostic stage groups.
Conclusions
The AJCC eighth edition prognostic stage provides more accurate prognostic information than the anatomic stage. Use of this staging system by cancer registrars will begin in January 2018. Before then, the AJCC will likely address the identified limitations, specifically the current combinations of T, N, and M categories with tumor grade and ER, PR, and HER2 status without a corresponding prognostic stage. Going forward, the prognostic stage will require frequent updates as additional information regarding the prognostic significance of other biologic factors to include Ki-67 and other genomic assays becomes available. 
